Innate Pharma S.A.
IPH.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €130 | €118 | €121 | €160 |
| - Cash | €54 | €66 | €70 | €71 |
| + Debt | €27 | €31 | €36 | €40 |
| Enterprise Value | €103 | €82 | €86 | €129 |
| Revenue | €5 | €8 | €12 | €21 |
| % Growth | -37.5% | -37% | -42.4% | – |
| Gross Profit | -€16 | -€15 | -€17 | -€3 |
| % Margin | -322.2% | -194.5% | -135.5% | -14.6% |
| EBITDA | -€25 | -€23 | -€26 | -€10 |
| % Margin | -515.7% | -296.5% | -207.1% | -48.5% |
| Net Income | -€21 | -€25 | -€25 | -€9 |
| % Margin | -439.2% | -317.7% | -200.6% | -43.3% |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.11 |
| % Growth | 16.7% | 3.2% | -181.8% | – |
| Operating Cash Flow | -€31 | -€10 | €3 | -€21 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€31 | -€10 | €3 | -€21 |